Search results for "VIRUS"

showing 10 items of 5024 documents

Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily.

2009

The virus that causes Kaposi sarcoma, KS-associated herpesvirus (KSHV, also known as human herpesvirus 8) has an unusual distribution and poorly characterized modes of transmission. To clarify these issues, socio-demographic correlates of KSHV seroprevalence were examined in a population-based study. In 1,154 randomly sampled adults (aged 32- 92, mean 71 years) throughout Sicily, KSHV antibodies were detected with four assays and a conservative algorithm. Seroprevalence was re-weighted to the population. Odds ratios with 95% confidence intervals (OR, CI) from multivariate logistic regression were used to estimate associations of seroprevalence with interview data. KSHV seroprevalence was 8.…

AdultMalemedicine.medical_specialtyPopulationLogistic regressionAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataArticleSerologyRisk FactorsSeroepidemiologic StudiesVirologyEpidemiologymedicineSeroprevalenceGammaherpesvirinaeHumanseducationSicilyAgedAged 80 and overeducation.field_of_studybiologybusiness.industryOdds ratioHerpesviridae InfectionsMiddle Agedbiology.organism_classificationVirologyKSHV seroprevalence socio-economic correlates elderly SicilyConfidence intervalInfectious DiseasesSocioeconomic FactorsHerpesvirus 8 HumanFemalebusiness
researchProduct

Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice

2015

Producción Científica

AdultMalemedicine.medical_specialtyRiñones - TrasplanteCongenital cytomegalovirus infectionCytomegaloviruskidney transplantationSIDA (Enfermedad)Kaplan-Meier EstimateDiseaseAntiviral AgentsAsymptomaticRisk FactorsInternal medicineseropositive recipientpreemptive therapymedicineHumansValganciclovirProspective StudiesRenal InsufficiencyPropensity ScoreGanciclovircytomegalovirusKidney transplantationAgedProportional Hazards ModelsTransplantation3205.06 Nefrologíabusiness.industryProportional hazards modelIncidenceIncidence (epidemiology)antiviral prophylaxisMiddle Agedmedicine.diseaseKidney TransplantationDiscontinuationSurgerymulticenter studySpainCytomegalovirus InfectionsPropensity score matchingFemalemedicine.symptombusinessImmunosuppressive AgentsGlomerular Filtration Rate
researchProduct

Prevalence of salivary Epstein-Barr virus in potentially malignant oral disorders and oral squamous cell carcinoma.

2015

Background: To analyze the presence of salivary Epstein-Barr virus (EBV) DNA in oral squamous cell carcinoma and potentially malignant oral disorders. Material and Methods: Three groups were studied: Group 1 (12 oral squamous cell carcinomas (OSCC)), Group 2 (12 potentially malignant oral disorders (PMD)) and Group 3 (47 healthy controls). EBV DNA salivary analysis was performed by PCR. Results: The highest percentage of positive salivary EBV DNA corresponded to the OSCC group (58.3%), followed by the PMD group (41.7%) and the controls (40.4%). The differences between groups were not statistically significant, however (p>0.05). Conclusions: Salivary EBV DNA was more prevalent in OSCC than i…

AdultMalemedicine.medical_specialtySalivaHerpesvirus 4 HumanCellOdontologíamedicine.disease_causeGastroenterologyVirus03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineCarcinomamedicineHumansBasal cellYoung adultSalivaGeneral DentistryAgedMouth neoplasmAged 80 and overOral Medicine and Pathologybusiness.industryResearch030206 dentistryMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Epstein–Barr virusCiencias de la saludstomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASImmunologyDNA ViralCarcinoma Squamous CellSurgeryFemaleMouth NeoplasmsbusinessMouth DiseasesMedicina oral, patologia oral y cirugia bucal
researchProduct

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomi…

2006

AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR)…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicavirusesHepacivirusAlpha interferonHepacivirusPharmacologyGastroenterologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInterferonRecurrenceInternal medicineRibavirinmedicineHumansIn patientSettore MED/12 - GastroenterologiabiologyDose-Response Relationship Drugbusiness.industryRibavirinGastroenterologyInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationhumanitiesRecombinant ProteinsTreatment OutcomechemistryInterferon Type IInterferon Ribavirin Hepatitis C virus Hepatitis C RelapserDrug Therapy CombinationFemalebusinessViral loadInterferon type IRapid Communicationmedicine.drugWorld journal of gastroenterology
researchProduct

Insulin-resistance HCV infection-related affects vascular stiffness in normotensives

2015

BACKGROUND AND AIMS. Arterial stiffness evaluated as pulse wave velocity, is an early marker of vascular damage and an independent predictor for cardiovascular events. We investigated if the insulin resistance/hyperinsulinemia chronic hepatitis C virus infection-related could influence arterial stiffness. METHODS. We enrolled 260 outpatients matched for age, body mass index, gender, ethnicity: 52 with never-treated uncomplicated chronic hepatitis C virus infection (HCV(+)), 104 never-treated hypertensives (HT) and 104 healthy subjects (NT). Pulse wave velocity was evaluated by a validated system employing high-fidelity applanation tonometry. We also measured: fasting plasma glucose and insu…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentArterial stiffness; Chronic hepatitis C virus infection; Insulin resistanceInsulin resistance; chronic hepatitis C virus infection; arterial stiffnessBlood PressurePulse Wave AnalysisBody Mass Indexchemistry.chemical_compoundVascular StiffnessInsulin resistanceRisk FactorsHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinPulse wave velocityCreatinineTriglyceridebusiness.industryInsulinInsulin resistanceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseArterial stiffnearterial stiffnessEndocrinologychemistryCase-Control StudiesHypertensionLinear ModelsArterial stiffnessFemaleCardiology and Cardiovascular MedicinebusinessChronic hepatitis C virus infection
researchProduct

Aligning personal and collective interests in emerging adults during the COVID-19 emergency in Italy

2021

This study investigated the relations of emerging adults' personal (civic competence and interdependent self-construal) and community-based (sense of community and civic engagement) resources as predictors of appraisal of COVID-19 Public Health Emergency Management (PHEM) and attitudes toward preventing contagion in Italy. Participants were 2873 Italian emerging adults (71% females) aged 19-30 years (M = 22.67, SD = 2.82). Structural equation modeling revealed both direct and indirect positive associations among study variables. Civic competence and interdependent self-construal were related to sense of community and civic engagement behavior which, in turn, predicted appraisal of PHEM. App…

AdultMalemedicine.medical_specialtySocial PsychologyCoronavirus disease 2019 (COVID-19)media_common.quotation_subjectcivic engagementSense of communitycivic competence; civic engagement; COVID-19; interdependent self-construal; Public Health Emergency Management; Adult; Female; Humans; Italy; Male; COVID-19Structural equation modelingcivic competenceinterdependent self-construalmedicineCivic engagementHumansCompetence (human resources)media_commonEmergency managementbusiness.industryPublic healthCOVID-19InterdependencePublic Health Emergency ManagementItalyFemalebusinessPsychologycivic competence civic engagement COVID‐19 interdependent self‐construal Public Health Emergency ManagementSocial psychology
researchProduct

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.

2006

BACKGROUND The efficacy of consensus interferon (CIFN), a synthetic IFN with optimised in vitro activity, was assessed in chronic hepatitis C virus (HCV) patients who had failed the pretreatment with interferon-alpha (IFNalpha) and ribavirin. METHODS One hundred and three patients after non-response (n=69) or relapse (n=34) to IFNalpha+/-ribavirin were randomly assigned to high-dose induction (CIFN 27-->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) or low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks); each with ribavirin 800 mg/day. Follow-up was 24 weeks. RESULTS Non-responder patients treated with high-dose induction had higher early virolo…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentConsensus interferonAlpha interferonHepacivirusGastroenterologyAntiviral AgentsVirusVirological responsechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinMedicineHumansIn patientDosingProspective StudiesAgedHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis C ChronicMiddle AgedViral Loaddigestive system diseasesTreatment OutcomechemistryResearch DesignImmunologyFemaleInterferonsbusinessBiomarkersFollow-Up StudiesLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks

2011

Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.We treated 398 treatment-naïve patients who had HCV genotype 1 infections with pegylated interferon alfa-2b and ribavirin for 24, 30, 36, 42, 48, 60, or 72 weeks (mean of 39 weeks, termed individualized therapy); the duration of therapy was determined based on baseline viral load and the time point at which HCV RNA levels became undetectable (measured at weeks 4, 6, 8, 12, 24, and 30). Results were compared with…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeTranscription-mediated amplificationHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyVirusPolyethylene GlycolsYoung AdultLiver diseasechemistry.chemical_compoundPegylated interferonGermanyInternal medicineRibavirinHumansMedicinePrecision MedicineAgedDose-Response Relationship DrugHepatologybusiness.industryStandard treatmentRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical trialTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drugGastroenterology
researchProduct

Diabetes mellitus association with coronavirus disease 2019 ( COVID ‐19) severity and mortality: A pooled analysis

2020

Highlights There are ~ 2-fold increased odds of severe coronavirus disease 2019 (COVID-19) and a ~ 2-fold increased risk of odds of mortality in patients with history of diabetes mellitus compared to those without diabetes mellitus. Patients with a history of diabetes mellitus should be closely monitored if they get infected with COVID-19. Results of meta-analysis showing association of diabetes mellitus with severity (Panel A) of disease and mortality (Panel B) in coronavirus disease 2019 (COVID-19) patients.

AdultMalemedicine.medical_specialtyTime FactorsAdolescentendocrine system diseasesEndocrinology Diabetes and MetabolismPneumonia Viralcoronavirus030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologymedicine.disease_causeRisk AssessmentSeverity of Illness IndexCOVID-19 coronavirus diabetes mellitusBetacoronavirusYoung Adult03 medical and health sciences0302 clinical medicineCOVID‐19Risk FactorsCause of DeathInternal medicineDiabetes mellitusPandemicSeverity of illnessResearch LetterHumansMedicineYoung adultPandemicsAgedCoronavirusCause of deathAged 80 and overSARS-CoV-2business.industryCOVID-19Middle AgedPrognosismedicine.diseaseResearch LettersHost-Pathogen Interactionsdiabetes mellitusFemaleCoronavirus InfectionsbusinessRisk assessmentJournal of Diabetes
researchProduct

Long-term course of interferon-treated chronic hepatitis C

1998

Abstract Background/Aims: To evaluate whether sustained response to α-interferon improves clinical outcome in patients with chronic hepatitis C. Methods: A cohort of 410 consecutive patients (65% with chronic hepatitis, 35% with cirrhosis) were treated with α-interferon in two trials (mean follow-up 62.1 months, range 7–109 months). All were serum HCV RNA positive before therapy and received first 10 then 5 million units of α-2b or α-n1 interferon three times weekly for 6 to 12 months. Sustained response was defined as normal aminotransferases 12 months after stopping interferon. Results: Sixty-two patients (15.1%: 54 with chronic hepatitis, eight with cirrhosis) were sustained responders. …

AdultMalemedicine.medical_specialtyTime FactorsCirrhosisHepacivirusHepatitis C virusStatistics as TopicAlpha interferonmedicine.disease_causeAntiviral AgentsGastroenterologyLiver diseaseInternal medicineAscitesmedicineHumansInterferon alfaHepatologybiologybusiness.industryInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseTreatment OutcomeImmunologyFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Hepatology
researchProduct